Primary Clinical Response of Relmacabtagene Autoleucel in Adults with Relapsed/Refractory Follicular Lymphoma (r/r FL) in ChinaBackground Most patients (pts) with r/r FL remain incurable and eventually relapse or progress. Previously, a Ph1 study of relma-cel (NCT03344367) had demonstrated ...
瑞基奥仑赛注射液(Relmacabtagene Autoleucel、倍诺达、relma-cel、Carteyva)成为我国第一个拥有三大适应症的CAR-T产品 据“上海市浦东新区人民政府”官网消息,2024年8月27日,中国国家药品监督管理局(NMPA)已批准瑞基奥仑赛注射液的补充生物制品许可申请(sBLA),用于成人复发或难治性套细胞淋巴瘤(r/r MCL)的治疗。
Relmacabtagene autoleucel 瑞基奥仑赛注射液(倍诺达®)说明书 药物: Relmacabtagene autoleucel 瑞基奥仑赛注射液(倍诺达®) 中国上市:已上市 治疗: 大B细胞淋巴瘤,复发或难治性B细胞急性淋巴细胞白血病 参考用法用量: 详见说明书 不良反应:
9月3日,药明巨诺靶向CD19自体嵌合抗原受体(CAR)T细胞疗法瑞基仑赛(relmacabtagene autoleucel,relma-cel)注射液(受理号:CXSS2000036)已获国家药监局批准上市。是继复星凯特阿基仑赛之后国内获批的第2款CAR-T细胞疗法。 Relma-cel此次获批适应症为:用于治疗经过二线或以上全身性治疗后成人患者的复发或难治性大B细胞...
Relmacabtagene autoleucel injection (abbreviated as relma-cel, trade name: Carteyva®) is an autologous anti-CD19 CAR-T cell immunotherapy product independently developed by JW Therapeutics based on a CAR-T cell process platform of Juno Therapeutics (a Bristol Mye...
La inyección relmacabtagene autoleucel (nombre comercial: Carteyva®) es un producto de inmunoterapia de células T autólogas anti-CD19 desarrollado de manera independiente por JW Therapeutics con base en una plataforma de procesamiento de célul...
À propos de l'injection de relmacabtagene autoleucel (nom commercial : Carteyva®) L'injection de relmacabtagène autoleucel (nom commercial : Carteyva®) est un produit d'immunothérapie cellulaire autologue CAR-T anti-CD19 qui a été...
About Relmacabtagene Autoleucel Injection (trade name: Carteyva®) Relmacabtagene autoleucel injection (abbreviated as relma-cel, trade name: Carteyva®) is an autologous anti-CD19 CAR-T cell immunotherapy product independently develo...
中国上海,2021年9月6日– 药明巨诺(港交所代码:2126),一家专注于开发、生产及商业化细胞免疫治疗产品的创新型生物科技公司,宣布中国国家药品监督管理局(NMPA)已批准其靶向CD19的自体嵌合抗原受体T(CAR-T)细胞免疫治疗产品倍诺达®(瑞基奥仑赛注射液,研发代号JWCAR029)的新药上...